Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

RegenxBio: An analyst and investor event focused on the firm’s ophthalmology program.

February 15, 2019 0

RegenxBio (RGNX), a clinical-stage gene therapy firm with a proprietary NAV® Technology Platform, will host an analyst and investor event focused on its ophthalmology program; including its lead product candidate RGX-314, on Thursday, February 21, 2019, from 9:00 a.m. to 12:00 p.m. EST in New York City. A live webcast will be available on the company’s website. The agenda will include discussion on RegenxBio’s NAV® Technology Platform, a review of the …

Successful results were announced by uniQure for its gene therapy,...

RegenxBio product RGX-181 has been granted FDA Rare Pediatric Disease...

OncoCyte liquid biopsy proves its accuracy and superiority in the...

CompuGen demonstrates the importance of its product COM701 targeting PVRIG...

Another drug approval for Exelixis. Why Alnylam’s stock is under...

Why the new approval of Exelixis’ blood pressure drug Minnebro...

The importance of the FDA granting Fast Track Designation to...

Rhythm Pharmaceutical: Updates on trial results from genetic-derived obesity

Gilead: On the road towards realizing its goals. A new...

Agenus: Signing a lucrative and rewarding agreement with Gilead

AstraZeneca: Excellent collaborations. Moderna Therapeutics: Turning public. Will Prohost add...

A follow up on Gilead’s latest news

Exelixis initiates a phase 3 trial with cabozantinib combination for...

Celgene has important CAR T presentations at ASH

Vertex: Offering proof of leadership in treating Cystic Fibrosis

Loxo Oncology product Vitrakvi® has been granted FDA approval. The...

What the Aimmune and Nestlé Health Science agreement tells us

Jazz Pharmaceuticals has good, not bad news

RegenxBio: Another licensing agreement providing additional validation of its NAV...

Today’s Highlights

Nektar presentation today at the ASCO genitourinary cancers symposium

February 15, 2019 0

Today, at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (GU) held at …

Exelixis’ excellent scientific and financial accomplishments

February 13, 2019 0

Exelixis’ (EXEL) financial results for the fourth quarter and full year 2018 are as inspiring as they are …

Portola: On the right track

February 12, 2019 0

Portola Pharmaceuticals (PTLA) announced full results from ANNEXA-4, Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa® in …

ImmunoGen report and standing. Why Biogen is experiencing a Selloff

February 8, 2019 0

ImmunoGen (IMGN) is a creator and developer of antibody-drug conjugates (ADCs) aimed at improving cancer treatments. ImmunoGen …

Halozyme signs another license agreement this time with argenx

February 5, 2019 0

Halozyme Therapeutics (HALO) and argenx (ARGX) announced a global collaboration and license agreement offering argenx the right to use …

Merck’s superior accomplishments

February 1, 2019 0

Merck (MRK) announced its Q4 2018 financial results. The firm outperformed itself and delighted us with regard …

Agenus fincances through Tokenization. Amgen’s critics hit hard. Why BioTime could thrive on OncoCyte news

January 30, 2019 0

AGENUS Agenus (AGEN) announced the upcoming launch of its Biotech Electronic Security Token (BEST); the first digital security …

Lipocine’s product, LPCN-1144, has promising results in decreasing the risk of NASH in non-alcoholic fatty liver disease

January 17, 2019 0

Lipocine (LPCN), a specialty pharmaceutical company, announced that an approximately eight-week top-line study using LPCN 1144 …

The FDA committee voted 19 to 1 in favor of approving Amgen’s & UCB’s new osteoporosis product Evenity

January 17, 2019 0

On January 8, 2019 the osteoporosis monoclonal antibody Evenity (romosozumab) developed by Amgen and UCB was …

Japan approved Gilead’s product Epclusa®. See Also: A collaboration agreement with Yuhan

January 8, 2019 0

Gilead Sciences (GILD) has news that begins with an announcement today that Japan’s Ministry of Health, Labour and …

The Week in Review

Now You See It, Now You Don’t

January 28, 2019 0

Now You See it, Now You Don’t Deliberate Omissions of Real Facts Real facts might be …

Politics and the Market

December 11, 2018 0

The Week in Review #35 Politics and the Market The market tumbled today as Theresa May, …

Improving on immunotherapy and preventing one of its serious side effects

November 13, 2018 0

The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. …

We call it the bad market

October 30, 2018 0

The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of …

Positive News

October 22, 2018 0

The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-stage …

Outperformance, underperformance and volatility

October 2, 2018 0

The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY …

Three important news

September 25, 2018 0

The Week in Review #30 FROM THE DEPARTED WEEK In the past week, we came across …

What is looking good in the aggressive portfolio

September 10, 2018 0

The Week in Review #29 PROHOST AGGRESSIVE PORTFOLIO - The aggressive portfolio hosts biotech firms with …

Outperforming, favorite, and undervalued biotech firms

September 3, 2018 0

The Week in Review #28 The approval of revolutionary products created by biotech firms with solid …

Bombarding future treatment approaches

August 15, 2018 0

The Week in Review #27 PRIORITY TOPICS: CRISPR GENE EDITING, GENETIC ENGINEERING & ANTISENSE TECHNOLOGY The choice of these …

Prohost Letters

End of the Year Decisions ~ Part 3

February 10, 2019 0

Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this …

End of the Year Decisions Part 2

January 24, 2019 0

Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected …

End of the Year Decisions ~ Part 1

January 15, 2019 0

Prohost Letter #426 End of the Year Decisions ~ Part 1 We decided to make this …

The NEW Prohost Portfolio for 2019

January 3, 2019 0

The NEW Prohost Portfolio Small Important Changes We are making some very small but important changes …

When common sense fails to explain market performance

December 3, 2018 0

Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual …

Following the Stars. Less Science and More Logic

October 14, 2018 0

Prohost Letter #424 Following the Stars Less Science and More Logic We reiterate that while a …

Victims of fear and misunderstanding

August 1, 2018 0

ProhostLetter #423 TOMORROW’S THERAPEUTICS TODAY For a more or less fair evaluation of biotechnology and pharmaceutical …

New stock selection and re-evaluation

June 8, 2018 0

Prohost Letter #422 SUMMARY OF THE PAST ISSUE ARTICLE - REVISITING PROMISING FIRMS (PART1) - The …

Revisiting Biotech Companies We Highlighted

May 25, 2018 0

Prohost Letter #421 PRIVATE LESSONS - Stock prices of publicly-traded biotech companies oscillate for the same …

Real Breakthroughs

April 17, 2018 0

Prohost Letter #420 REAL BREAKTHROUGHS - One Has Already Been Used and the Other Has Extraordinary …